个人信息

头像

姓名: 陈良

部门: 生命科学技术学院

直属机构: 生化与分子生物学系(生命与健康工程研究院)

性别:

职务: 实验室主任

职称: 研究员

学位: 博士

毕业院校: 中国科学院上海生物化学与细胞生物学研究所

联系电话: 020-85222875

电子邮箱: chenliang@email.jnu.edu.cn

办公地址: 暨南大学第二理工楼6楼643办公室

通讯地址: 暨南大学第二理工楼6楼643办公室

邮编: 510632

传真:

荣誉奖励: 珠江学者

联系方式

130 5121 1182

020-8522 2875


个人简介

陈良,男。研究员,科技部973计划首席科学家,珠江学者特聘教授。

2002年博士毕业于中国科学院上海生物化学与细胞生物学研究所;2002-2005耶鲁大学医学院博士后;2005-2010哈佛大学医学院博士后,期间提出了第三代EGFR抑制剂的概念,参与WZ4002的研制(Nature 2009,第一作者),为奥希替尼的研制奠定了基础;2010-2016年回国后,在北京生命科学研究所组建实验室;2016至今,在暨南大学生命科学技术学院组建实验室,研究肺癌的癌变机理和精准治疗。

陈良博士领导的实验室系统的鉴定了肺癌的抑癌基因,解析了抑癌基因发挥作用的信号传导机制,据此制定并证实了多个肺癌的精准治疗方案。陈良博士实验室开发了抗癌药物,包括全新概念的PD-1抑制(EMBO Molecular Medicine 2020,通讯作者;专利已转让,第一发明人),Tankyrase抑制剂,EML4-ALK的第二代抑制(EMBO Molecular Medicine 2021,共同通讯作者),靶向肿瘤相关巨噬细胞(TAM)的小分子药物(将TAM转化为M1型巨噬细胞)(EMBO Molecular Medicine 2021,通讯作者)。近5年,发表PNASNature CommunicationsEMBO molecular medicineTheranostics等杂志通讯作者科学论文20篇。

陈良博士曾主持、承担973课题、国自然面上项目、以及国家重点研发计划精准医学专项、广东省科技计划重点项目、广州市科技计划项目民生科技攻关计划等项目。

学习经历

2002: PhD, Shanghai Institute of Biochemistry and Cell Biology, CAS, China

1997: BSc, Hangzhou University, China


工作经历

2016 - Present: Professor, Jinan University, China

2010 – 2016: Professor, National Institute of Biological Sciences, Beijing

2005 – 2010: Postdoc - Dana-Farber Cancer Institute, Harvard Medical School, USA

2002 – 2005: Yale School of Medicine, USA


研究方向

开展肺癌的早期诊断、肺癌的癌变机理及肺癌的治疗研究。

主要论文

  1. Zhou Q., Liang J., Yang T., Liu J., Li B., Li Y., Fan Z., Wang W., Chen W., Yuan S., Xu M., Xu Q., Luan Z., Xia Z., Zhou P., Huang Y., Chen L., Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO Mol Med. 13 December 2021e14502. doiorg/10.15252/emmm.202114502

  2. Yue Lu Fan Z., Zhu S., Huang X., Zhuang Z., Li Y., Deng Z., Gao L., Hong X., Zhang T., Sun X., Huang W., Zhang J., Liu Y., Zhang B., Jiang J., Gui F., Wang., Li Q., Song S., Huang X., Wu Q., Chen L., Zhou D., Zhang J#., Yun C#., Chen L#, Deng X#., A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. EMBO Mol Med. 2021 Nov 30:e14296. doi: 10.15252/emmm.202114296

  3. Qin Z, Sun H, Yue M, Pan X, Chen L, Feng X, Yan X, Zhu X, Ji H, Phase separation of EML4-ALK in firing downstream signaling and promoting lung tumorigenesis. Cell Discov. 2021 May 11;7(1):33.5

  4. Zhou Q, Chen W, Fan Z, Chen Z, Liang L, Zeng G, Liu L, Liu W, Yang T, Cao X, Yu B, Xu M, Chen Y, Chen L. Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer. Theranostics. 2021; 11(13): 6592–6606.

  5. Chen Z, Fan Z, Dou X, Zhou Q, Zeng G, Liu L, Chen W, Lan R, Liu W, Ru G, Yu L, He Q, Chen L. Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity. Theranostics. 2020; 10(25): 11520-11534. doi: 10.7150/thno.44829

  6. Fan Z#, Tian Y#, Chen Z, Liu L, Zhou Q, He J, Coleman J, Dong C, Li N, Huang J, Xu C, Zhang Z, Gao S, Zhou P, Ding K, Chen L. Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors, EMBO Mol Med. 2020 May 11:e11571. doi: 10.15252/emmm.201911571

  7. Li B, Liang J, Lu F, Zeng G, Zhang J, Ma Y, Liu P, Wang Q, Zhou Q, Chen L, Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening. Molecules. 2020 Apr 6;25(7). pii: E1680. doi: 10.3390/molecules25071680.

  8. Lu F, Zhou Q, Liu L, Zeng G, Ci W, Liu W, Zhang G, Zhang Z, Wang P, Zhang A, Gao Y, Yu L, He Q, Chen L., A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients, Theranostics, 2020; 10(2): 484-497. doi: 10.7150/thno.38060

  9. GaoL., Hu Y., Tian Y., Fan Z., Wang K., Li H., Zhou Q., Zeng G., Hu X., Yu L., Zhou Sh., Tong X., Huang H., Chen H., Liu Q., Liu W., Zhang G., Zeng M., Zhou G., He Q., Ji H., Chen L., Lung Cancer Deficient in the Tumor Suppressor GATA4 are Sensitive to TGFBR1 InhibitionNature Communications, 2019 Apr 10;10(1):1665. doi: 10.1038/s41467-019-09295-7

  10. Wu Q, Tian Y, Zhang J, Tong X, Huang H, Li S, Zhao H, Tang Y, Yuan C, Wang K, Fang Z, Gao L, Hu X, Li F, Qin Z, Yao S, Chen T, Chen H, Zhang G, Liu W, Sun Y, Chen L, Wong KK, Ge K, Chen L#, Ji H. In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E3978-E3986. (# co-corresponding)

  11. Li S, Jiang Q, Liu S, Zhang Y, Tian Y, Song C, Wang J, Zou Y, Anderson G, Han J, Chang Y, Liu Y, Zhang C, Chen L, Zhou G, Nie G, Yan H, Ding B & Zhao Y. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat Biotechnol. 2018 Feb 12. doi: 10.1038/nbt.4071

  12. Gao R, Xiu W, Zhang L, Zang R, Yang L, Wang C, Wang M, Wang M, Yi L, Tang Y, Gao Y, Wang H, Xi J, Liu W, Wang Y, Wen X, Yu Y, Zhang Y, Chen L#, Chen J#, Gao S#.Direct induction of neural progenitor cells transiently passes through a partially reprogrammed state. Biomaterials. 2016 Dec 10;119:53-67. doi: 10.1016/j.biomaterials (# co-corresponding)

  13. Mikse OR, Tchaicha JH, Akbay EA, Chen L, Bronson RT, Hammerman PS, Wong KK., The impact of the MYB-NFIB fusion protooncogene in vivo. Oncotarget. 2016 May 18. doi: 10.18632/oncotarget.9426.

  14. Yang H, Zhang W, Lu S, Lu G, Zhang H, Zhuang Y, Wang Y, Dong M, Zhang Y, Zhou X, Wang P, Yu L, Wang F, and Chen L., Mup-knockout mice generated through CRISPR/Cas9-mediated deletion for use in urinary protein analysis. Acta Biochim Biophys Sin, 2016 May;48(5):468-73. doi: 10.1093/abbs/gmw003

  15. Zhang H, Zhan C, Ke J, Xue Z, Zhang A, Xu K, Shen Z, Yu L, Chen L., EGFR Kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment, Oncotarget, 2015 Dec 8. DOI: 10.18632/oncotarget.6491

  16. Xu N., Fang W., Mu L., Tang Y., Gao L., Ren S., Cao D., Zhou L., Zhang A., Liu D., Zhou C., Wong K., Yu L., Zhang L., Chen L., Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget, 2015 Dec 4. doi: 10.18632/oncotarget.6461

  17. Gao L., Jiang Y., Mu L., Liu Y., Wang F, Wang P., Zhang A., Tang N., Chen T., Luo M., Yu L., Gao S., Chen L. Efficient Generation of Mice with Consistent Transgene Expression by FEEST, Sci Rep. 2015, 5:16284; doi: 10.1038/srep16284

  18. Liu ZH, Hu JL, Liang JZ, Zhou AJ, Li MZ, Yan SM, Zhang X, Gao S, Chen L, Zhong Q, Zeng MS., Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression. Cell Death Dis. 2015 Oct 15;6:e1920

  19. Hu Z, Hu Y, Liu X, Xi R, Zhang A, Liu D, Xie Q and Chen L, Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor, Oncotaget, 2015 Oct 13;6(31):31628-39. doi: 10.18632/oncotarget.5221

  20. Wu H, Wang A, Zhang W, Wang B, Chen C, Wang W, Hu C, Ye Z, Zhao Z, Wang L, Li X, Yu K, Liu J, Wu J, Yan X, Zhao P, Wang J, Wang C, Weisberg E, Gray N, Yun C, Liu J, Chen L#, Liu Q#. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget, 2015 Oct 13;6(31):31313-22. doi: 10.18632/oncotarget.5182 (# co-corresponding)

  21. Zhang H, Cao J, Li L, Liu Y, Zhao H, Li N, Li B, Zhang A, Huang H, Chen S, Dong M, Yu L, Zhang J, Chen L.,Identification of urine protein biomarkers with the potential for early detection of lung cancer. Sci Rep. 2015 Jul 2;5:11805. doi: 10.1038/srep11805.

  22. Hu Z, Wan X, Hao R, Zhang H, Li L, Li L, Xie Q, Wang P, Gao Y, Chen S, Wei M, Luan Z, Zhang A, Huang N, Chen L., Phosphorylation of Mutationally Introduced Tyrosine in the Activation Loop of HER2 Confers Gain-of-Function Activity. PLoS One. 2015 Apr 8;10(4):e0123623.

  23. Zhu G, Fan Z, Ding M, Zhang H, Mu L, Ding Y, Zhang Y, Jia B, Chen L, Chang Z, Wu W, An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis. Oncogene. 2015 Mar 9. doi: 10.1038/onc.2015.45

  24. Ding X, Yang Y, Han B, Du C, Xu N, Huang H, Cai T, Zhang A, Han ZG, Zhou W, Chen L. Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation. PLoS One. 2014 May 5;9(5):e95307

  25. Chen Z, Akbay EA, Mikse OR, Tupper T, Cheng K, Wang Y, Tan X, Altabef A, Woo SA, Chen L, Reibel J, Janne PA, Engelman JA, Sharpless NE, Kung AL, Shapiro GI, Wong KK. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res. 2014 Mar 1;20(5):1204-11.

  26. Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich HE, Johnson BE, Eck MJ, Janne PA, Wong KK, Meyerson M. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 2013 Nov 15;73(22):6770-9

  27. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer. Clin Cancer Res. 2012 Sep 15;18(18):4973-85. Epub 2012 Jul 17.

  28. Straume O, Shimamura T, Lampa MJ, Carretero J, Oyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM, Kang SY, Wang S, Chen L, Collett K, Bachmann I, Wong K-K, Shapiro GI, Kalland KH, Folkman J, Watnick RS, Akslen LA, Naumov GN. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A. 2012 May 29;109(22):8699-704. Epub 2012 May 15

  29. Leng L, Chen L, Fan J, Greven D, Arjona A, Du X, Austin D, Kashgarian M, Yin Z, Huang XR, Lan HY, Lolis E, Nikolic-Paterson D, Bucala R. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J Immunol 2011 Jan 186 (1), 527-538.

  30. M-C Liang, J Ma, L Chen, P Kozlowski, W Qin, D Li, J Goto, T Shimamura1, DN Hayes, M Meyerson, DJ Kwiatkowski and K-K Wong, TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity, Oncogene, 2010 Mar 18;29(11):1588-97

  31. Zhou W(*), Ercan D(*), Chen L(*), Yun C(*), Li D, Capelletti M, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck M, Gray NS and Jänne PA., Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, 2009 Dec 24;462(7276):1070-4, (*equal contribution)

  32. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, Borgman CL, Zaghlul S, Brandstetter KA, Kubo S, Takahashi M, Chirieac LR, Padera RF, Bronson RT, Shapiro GI, Greulich H, Meyerson M, Guertler U, Chesa PG, Solca F, Wistuba II, Wong KK., HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy, Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):474-9.

  33. Engelman JA(*), Chen L (*), Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK., Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008 Dec;14(12):1351-6. (* equal contribution)

  34. Girnun GD (*), Chen L (*), Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, Li D, Force J, McNamara K, Demetri G, Spiegelman BM, Wong KK., Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res. 2008 Oct 15;14(20):6478-86. (* equal contribution)

  35. Perera SA, Maser RS, Xia H, McNamara K, Protopopov A, Chen L, Hezel AF, Kim CF, Bronson RT, Castrillon DH, Chin L, Bardeesy N, Depinho RA, Wong KK., Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. Carcinogenesis. 2008 Apr;29(4):747-53.

  36. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Jänne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK., LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007 Aug 16;448(7155):807-10.

  37. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jänne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272, Cancer Cell. 2007 Jul;12(1):81-93

  38. Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Jänne PA, Johnson BE, Chin L, Wong KK., Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 2007 May 15;67(10):4933-9.

  39. Chen L(*), He W(*), Kim ST, Tao J, Gao Y, Chi H, Intlekofer AM, Harvey B, Reiner SL, Yin Z, Flavell RA, Craft J.. Epigenetic and Transcriptional Programs Lead to Default IFN-gamma Production by gamma/delta T Cells. 2007 Mar; J Immunol. 178(5):2730-2736. (* equal contribution)

  40. Tao J, Gao Y, Li MO, He W, Chen L, Harvev B, Davis RJ, Flavell RA, Yin Z. JNK2 negatively regulates CD8(+) T cell effector function and anti-tumor immune response. Eur J Immunol. 2007 Mar;37(3):818-829.

  41. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK., The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006 Jun;9(6):485-95.

  42. Wisnewski AV, Stowe MH, Cartier A, Liu Q, Liu J, Chen L, Redlich CA., Isocyanate vapor-induced antigenicity of human albumin. J Allergy Clin Immunol. 2004 Jun;113(6):1178-1184.

  43. Wisnewski AV, Herrick CA, Liu Q, Chen L, Bottomly K, Redlich CA. Human gamma/delta T-cell proliferation and IFN-gamma production induced by hexamethylene diisocyanate. J Allergy Clin Immunol. 2003 Sep;112(3):538-546.

  44. Chen L, Li G, Tang L, Wang J, Ge XR, The inhibition of lung cancer cell growth by intracellular immunization with LC-1 ScFv. Cell Res. 2002 Mar;12(1):47-54.



主要著作

承担课题

--【在研】

Antidote Health Foundation For cure of CancerDeveloping small molecular agonist of NKP46 for NK cell mediated cancer immunotherapy20212023116.4万元,在研,主持

 

苏州信诺维医药科技股份有限公司,横向项目,XNW05项目机制研究服务,2021-06-252022-1220万元,在研,主持

 

南京红云生物科技有限公司,横向项目,RC01 TLCS肺癌小鼠模型中的药效学评价,2021-012021-1220万元,在研,参与

 

正大天晴药业集团股份有限公司,横向项目,TQB3602联合AK105在晚期非小细胞肺癌疾病中的基础研究,21.33万元,在研,参与

 

国家自然科学基金委员会面上项目,819727782020.01 – 2023.12),非小细胞肺癌干性抑癌基因的系统筛选及机理解析,项目负责人,55万元。

 

暨南大学高层次人才研究启动项目880174732017 – 2021),项目负责人,1,100万。在研。

 

广东省教育厅珠江学者特聘教授基金(2018.10-2021.9),200

 

暨南大学中央高校基本科研业务费(理工医)项目,新型PD-1小分子抑制剂的开发216191012019.01-2021.12),50万。在研

 

--【已结题】

科技部973重大科学专项2011CB8124012011.04 – 2013.12),抗癌小分子化合物的筛选和治疗效果的评价。课题负责人,1202万元。已结题

 

科技部973重大科学专项2011CB8124002011.06 – 2013.12)癌症中激酶机理的研究和在全新靶向药物分子开发中的应用,首席科学家3408万元。已结题

 

国家自然科学基金委员会面上项目814726062015.01 – 2018.12),中国肝癌和肺癌病人中HER2突变体对其蛋白功能影响及对靶向药物的反应机理的研究,项目负责人,72万元。已结题

 

国家自然科学基金委员会面上项目814721922015.01 – 2018.12),多环芳烃受体介导的肺癌EGFR-TKI耐药新机制实验研究,项目参与人,75万元。已结题

 

国家重点研发计划精准医学专项肺癌诊疗规范及应用方案的精准化研究2016YFC09055002016.07 – 2019.06),670.00万元。课题骨干,50万元。已结题

 

国家自然科学基金委应急管理项目(编号81550004),2016.01 – 2019.1212万元,胸腺和胸腺瘤差异基因的表达和筛选。已结题

 

广东省科技计划重点项目,晚期肺癌的精准医学临床应用研究2017B0202270012017.01 – 2021.12),300万。课题骨干,60万。在研

 

广州市科技计划项目民生科技攻关计划生物医药与健康专题,肺癌癌变机理及肺癌精准治疗方案的研究2018030101242018.04 – 2020.12),项目负责人,100万。在研

 

国家自然科学基金委员会面上项目,816723092017.01 – 2020.12),PD-1小分子抑制剂的开发与其作用分子机理和肺癌治疗的研究,项目负责人,52万元。

发明专利

1、陈良,高磊。一种评价EML-ALK抑制剂对肺癌治疗效果的方法,中国,申请号201710903091.3

2、陈良,范真真。吩噻嗪类或其类似结构的化合物在制药中的新应用,中国,申请号201910792478.5 (已转让)

3、王长利,张彬,陈良,马宇辰,陈智鹏,刘翠翠,岳东升,沙永生,田鹏飞,张华,潘家强,范真真。肺癌尿液分子标志物MDH2在用于肺癌辅助诊断方面的应用,中国,申请号201910647881.9

4、陈良,陈智鹏。一种治疗肺癌的药物,中国,申请号20191097204.3,专利号:ZL 2019 1 0972043.9

5、陈良,周倩。蛋白酶体抑制剂在抗癌药物中的应用,申请号202010823779.2


讲授课程

《肿瘤分子生物学》

《生物学前沿》

《高级生物学》

功能蛋白研究

众论生命科学

荣誉奖励

珠江学者

社会职务

2021.11至今Referee, Journal of Experimental & Clinical Cancer Research

2021.05至今 Referee, Clinical and Translational Medicine

2017.09至今 Editor, The Open Biomarkers Journal

2017.03至今 Editor, International Journal of Translational Research

2017至今 科技部国家重大科学研究计划评审专家

2014–2018 北京市第四届生物工程协会理事

2012–至今 农业部转基因重大专项评审专家

2018–至今 广东省创新创业团队项目评审专家

2018–至今 科技部干细胞及转化研究重大专项专项评审专家

2019–至今 广东省自然基金杰出青年项目评审专家

2018–至今 国家自然基金评审专家

2021至今 教育部“长江学者奖励计划”评审专家

2021至今 广东省人类疾病基因组重点实验室第四届学术委员会委员